• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Edesa Biotech Inc.

    2/25/25 5:16:20 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDSA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Edesa Biotech, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    27966L306

    (CUSIP Number)


    02/13/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    27966L306


    1Names of Reporting Persons

    Stonepine Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    693,551.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    693,551.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    693,551.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on (a) (1) 687,500 shares of Common Stock beneficially owned by the reporting person, and (2) 93,750 shares of Common Stock issuable on conversion of 18 shares of Series B-1 Convertible Preferred Stock beneficially owned by the reporting person, subject to a 9.99% beneficial ownership limitation, and (b) 6,936,404 shares of Common Stock outstanding on February 14, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    27966L306


    1Names of Reporting Persons

    Stonepine Capital, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    693,551.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    693,551.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    693,551.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on (a) (1) 687,500 shares of Common Stock beneficially owned by the reporting person, and (2) 93,750 shares of Common Stock issuable on conversion of 18 shares of Series B-1 Convertible Preferred Stock beneficially owned by the reporting person, subject to a 9.99% beneficial ownership limitation, and (b) 6,936,404 shares of Common Stock outstanding on February 14, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    27966L306


    1Names of Reporting Persons

    Stonepine GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    693,551.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    693,551.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    693,551.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Percentage calculated based on (a) (1) 687,500 shares of Common Stock beneficially owned by the reporting person, and (2) 93,750 shares of Common Stock issuable on conversion of 18 shares of Series B-1 Convertible Preferred Stock beneficially owned by the reporting person, subject to a 9.99% beneficial ownership limitation, and (b) 6,936,404 shares of Common Stock outstanding on February 14, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    27966L306


    1Names of Reporting Persons

    Jon M. Plexico
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    693,551.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    693,551.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    693,551.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on (a) (1) 687,500 shares of Common Stock beneficially owned by the reporting person, and (2) 93,750 shares of Common Stock issuable on conversion of 18 shares of Series B-1 Convertible Preferred Stock beneficially owned by the reporting person, subject to a 9.99% beneficial ownership limitation, and (b) 6,936,404 shares of Common Stock outstanding on February 14, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended December 31, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Edesa Biotech, Inc.
    (b)Address of issuer's principal executive offices:

    100 Spy Court, Markham, ON, Canada L3R 5H6
    Item 2. 
    (a)Name of person filing:

    Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    919 NW Bond Street, Suite 204 Bend, OR 97703
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    27966L306
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Stonepine: 693,551 Partnership: 693,551 General Partner: 693,551 Jon M. Plexico: 693,551
    (b)Percent of class:

    Stonepine: 9.9% Partnership: 9.9% General Partner: 9.9% Jon M. Plexico: 9.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0

     (ii) Shared power to vote or to direct the vote:

    Stonepine: 693,551 Partnership: 693,551 General Partner: 693,551 Jon M. Plexico: 693,551

     (iii) Sole power to dispose or to direct the disposition of:

    Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Stonepine: 693,551 Partnership: 693,551 General Partner: 693,551 Jon M. Plexico: 693,551

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Stonepine Capital Management, LLC
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member
    Date:02/25/2025
     
    Stonepine Capital, L.P.
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
    Date:02/25/2025
     
    Stonepine GP, LLC
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member
    Date:02/25/2025
     
    Jon M. Plexico
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Reporting person
    Date:02/25/2025
    Exhibit Information

    Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

    Get the next $EDSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EDSA

    DatePrice TargetRatingAnalyst
    12/20/2021$16.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep was granted 11,168 shares, increasing direct ownership by 2% to 512,990 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    2/2/26 5:01:02 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep was granted 10,444 shares, increasing direct ownership by 2% to 501,822 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    1/5/26 9:00:34 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep was granted 8,766 shares, increasing direct ownership by 2% to 491,378 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    12/2/25 6:01:01 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Edesa Biotech with a new price target

    HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

    12/20/21 6:08:21 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Nijhawan Pardeep bought $20,000 worth of shares (5,000 units at $4.00) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/25/24 7:00:59 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edesa Biotech Reports Fiscal Year 2025 Results

    TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business. During the year, the company initiated manufacturing activities for a Phase 2 study of Edesa's dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in patients with moderate-to-severe nonsegmental vitiligo. Edesa anticipates that recruitment will begin by midyear 2026, subject to the completion of clinical-grade drug manufacturing and regulatory approvals

    12/12/25 4:20:00 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Announces Upcoming Conference Schedule

    TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Vienna, Austria, November 3-5, 2025LSX Investival Showcase Europe, London, UK, November 17, 2025. Presentation at 3:45 pm GMT. To schedule a meeting with Edesa during the events, please contact conference organizers or the company directly at [email protected]. About Edesa Biotech, Inc. Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage

    10/31/25 4:30:00 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

    Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consistent safety and tolerability profile TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, today announced positive results from a Phase 3 study evaluating the company's drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respir

    10/28/25 7:45:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    SEC Filings

    View All

    Edesa Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Edesa Biotech, Inc. (0001540159) (Filer)

    12/12/25 4:45:26 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Edesa Biotech Inc.

    424B5 - Edesa Biotech, Inc. (0001540159) (Filer)

    12/12/25 4:40:32 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Edesa Biotech Inc.

    10-K - Edesa Biotech, Inc. (0001540159) (Filer)

    12/12/25 4:30:52 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Leadership Updates

    Live Leadership Updates

    View All

    Edesa Biotech Announces Chief Financial Officer Transition

    TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

    4/4/25 4:15:46 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

    TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

    6/27/23 8:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Appoints Strategy Expert to Board of Directors

    TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

    3/29/22 9:00:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Edesa Biotech Inc.

    SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

    11/1/24 8:50:52 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Edesa Biotech Inc.

    SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

    6/3/24 4:10:38 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Edesa Biotech Inc. (Amendment)

    SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)

    1/29/24 4:29:02 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care